Background There is a lack of contemporary data describing patients with left ventricular (LV) systolic dysfunction post ...

Myqorzo (aficamten) is a new therapy for oHCM, improving functional capacity and symptoms, with an annual cost of $108,400. The Myqorzo & You program provides personalized support, including insurance ...

Heart failure sounds alarming—and rightfully so. Yet approximately 6.5 million Americans currently live with this condition, many with the specific variant called systolic heart failure, and a ...

Living with a heart that struggles to pump effectively creates daily challenges for millions of Americans. Systolic heart failure fundamentally changes how patients experience everyday activities.

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCMSOUTH SAN FRANCISCO, Calif., ...

Demographic, systemic sclerosis (SSc)-specific, and cardiac factors raised the risk for left ventricular systolic dysfunction (LVSD) in a study of patients with SSc. Researchers used the Johns Hopkins ...

Chicago, IL - Prolongation of the QRS interval, an electrocardiographic marker for ventricular dyssynchrony, is present in more than a third of low-LVEF patients hospitalized for acute heart failure ...

The heart is a muscle like no other, beating 60 to 100 times per minute on average, around the clock. But when it grows weak, it can lead to serious problems: from debilitating shortness of breath and ...

Medically reviewed by Jeffrey S. Lander, MD Key Takeaways Heart failure happens when the heart can't pump enough blood throughout the body. Chronic heart failure often happens because of other medical ...

LBBB is linked to electrical abnormalities, causing inefficient heart pumping, dilation, and systolic dysfunction. The study found LBBB associated with increased heart failure risk, surpassing other ...